OncoMatch/Clinical Trials/NCT06477692
Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy
Is NCT06477692 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ENI using IMRT with or without chemotherapy for head and neck cancer.
Treatment: ENI using IMRT with or without chemotherapy — To determine the risk of solitary elective volume recurrence following involved nodal radiotherapy (INRT) versus elective nodal irradiation (ENI)
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage I, II, III, IVA, IVB (AJCC 7th edition)
Excluded: Stage I GLOTTIC CANCER, II GLOTTIC CANCER
Clinical stage I-IVB (AJCC, 7th edition); stages I-II glottic cancer are excluded
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic chemotherapy
Exception: prior chemotherapy for a remote cancer is allowable
Prior systemic chemotherapy for the study cancer; prior chemotherapy for a remote cancer is allowable.
Cannot have received: radiation therapy
Exception: if would result in overlap of radiation fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify